Overall Survival with Amivantamab-Lazertinib in
Summary
In this phase 3 randomized trial, amivantamab-lazertinib significantly improved overall survival versus osimertinib (HR 0.75; 95% CI 0.61–0.92) with 3-year OS 60% vs 51%. Grade ≥3 adverse events were more frequent with amivantamab-lazertinib (80% vs 52%), notably skin events, venous thromboembolism, and infusion reactions.
Key Findings
- Overall survival was significantly longer with amivantamab-lazertinib versus osimertinib (HR 0.75; P=0.005).
- Three-year overall survival: 60% vs 51% (amivantamab-lazertinib vs osimertinib).
- Grade ≥3 adverse events were more frequent with amivantamab-lazertinib (80% vs 52%), especially skin-related events, venous thromboembolism, and infusion reactions.
- At data cutoff, ongoing treatment rates were 38% vs 28% (amivantamab-lazertinib vs osimertinib).
Clinical Implications
If adopted, therapy selection may shift toward amivantamab-lazertinib in the first-line setting, with proactive monitoring and management of skin toxicity, venous thromboembolism, and infusion reactions.
Why It Matters
Demonstrates an overall survival advantage of a novel combination targeted regimen over the current standard comparator in previously untreated patients, representing a potential change in first-line therapy.
Limitations
- Higher toxicity with amivantamab-lazertinib may limit tolerability for some patients.
- Abstract lacks detail on subgroup biomarker stratification and quality-of-life outcomes.
Future Directions
Define biomarker-driven subgroups benefiting most from amivantamab-lazertinib, optimize toxicity mitigation strategies, and assess quality-of-life and cost-effectiveness.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Randomized phase 3 trial with overall survival endpoint.
- Study Design
- OTHER